Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA, USA.
The University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, PA, USA.
Ann Surg Oncol. 2019 May;26(5):1445-1453. doi: 10.1245/s10434-019-07218-w. Epub 2019 Mar 1.
We hypothesized that repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) for peritoneal metastases (PM) may be associated with suboptimal resection, more frequent postoperative complications, and worse oncologic outcomes.
Using a prospectively maintained database, we compared clinicopathologic, perioperative, and oncologic outcome data in patients undergoing single or repeat CRS-HIPEC procedures. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with perioperative and oncologic outcomes.
Of the 1294 patients undergoing CRS-HIPEC procedures at our institution, only one CRS-HIPEC procedure (single HIPEC cohort) was performed in 1169 patients (90.3%), whereas 125 patients (9.7%) underwent repeat CRS-HIPEC procedures (repeat HIPEC cohort). Of the 1440 CRS-HIPEC procedures at our institution, a first CRS-HIPEC procedure was performed in 1294 patients (89.9%), whereas subsequent second, third, and fourth CRS-HIPEC procedures were performed in 125 patients (8.7%), 18 patients (1.3%), and 3 patients (0.2%), respectively. Progression-free survival (PFS) following the second CRS-HIPEC procedure was negatively impacted by shorter PFS following the first CRS-HIPEC procedure, independent of other significant variables related to the second procedure, including completeness of cytoreduction and postoperative complications. Patients undergoing multiple CRS-HIPEC procedures were not at higher risk for suboptimal resection or postoperative complications and demonstrated equivalent PFS following each successive procedure compared to the first procedure.
Repeat CRS-HIPEC procedures for PM were not associated with suboptimal perioperative and oncologic outcomes. Our data confirmed our ability to select patients appropriately for repeat CRS-HIPEC procedures.
我们假设对于腹膜转移(PM)的重复细胞减灭术-腹腔内热灌注化疗(CRS-HIPEC)可能与不充分的切除、更频繁的术后并发症和更差的肿瘤学结果相关。
我们使用前瞻性维护的数据库,比较了接受单次或重复 CRS-HIPEC 手术的患者的临床病理、围手术期和肿瘤学结局数据。Kaplan-Meier 方法用于估计生存。多变量分析确定了与围手术期和肿瘤学结局相关的因素。
在我们机构接受 CRS-HIPEC 手术的 1294 名患者中,仅有 1169 名患者(90.3%)接受了单次 CRS-HIPEC 手术(单次 HIPEC 队列),而 125 名患者(9.7%)接受了重复 CRS-HIPEC 手术(重复 HIPEC 队列)。在我们机构的 1440 次 CRS-HIPEC 手术中,1294 名患者(89.9%)接受了首次 CRS-HIPEC 手术,而随后的第二次、第三次和第四次 CRS-HIPEC 手术分别在 125 名患者(8.7%)、18 名患者(1.3%)和 3 名患者(0.2%)中进行。第二次 CRS-HIPEC 手术后的无进展生存期(PFS)受到首次 CRS-HIPEC 手术后较短 PFS 的负面影响,这与与第二次手术相关的其他重要变量无关,包括细胞减灭的完整性和术后并发症。接受多次 CRS-HIPEC 手术的患者并没有更高的风险出现不充分切除或术后并发症,并且与首次手术相比,在随后的每次手术中都表现出等效的 PFS。
PM 的重复 CRS-HIPEC 手术与围手术期和肿瘤学结果不佳无关。我们的数据证实了我们能够适当地选择接受重复 CRS-HIPEC 手术的患者。